vs
Amneal Pharmaceuticals, Inc.（AMRX）与Cloudflare, Inc.（NET）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是Cloudflare, Inc.的1.3倍（$814.3M vs $614.5M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs -2.0%，领先6.3%），Cloudflare, Inc.同比增速更快（33.6% vs 11.5%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $105.2M），过去两年Cloudflare, Inc.的营收复合增速更高（27.4% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Cloudflare是总部位于美国加利福尼亚州旧金山的科技企业，提供内容分发网络（CDN）、云网络安全、DDoS防护等多元互联网服务，同时是ICANN认证的域名注册商。其服务作为网站访客与客户托管服务商之间的反向代理，可有效提升访问性能，抵御恶意流量。
AMRX vs NET — 直观对比
营收规模更大
AMRX
是对方的1.3倍
$614.5M
营收增速更快
NET
高出22.1%
11.5%
净利率更高
AMRX
高出6.3%
-2.0%
自由现金流更多
AMRX
多$3.3M
$105.2M
两年增速更快
NET
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $614.5M |
| 净利润 | $35.1M | $-12.1M |
| 毛利率 | 36.5% | 73.6% |
| 营业利润率 | 13.8% | -8.0% |
| 净利率 | 4.3% | -2.0% |
| 营收同比 | 11.5% | 33.6% |
| 净利润同比 | 212.9% | 6.0% |
| 每股收益（稀释后） | $0.10 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXNET
| Q4 25 | $814.3M | $614.5M | ||
| Q3 25 | $784.5M | $562.0M | ||
| Q2 25 | $724.5M | $512.3M | ||
| Q1 25 | $695.4M | $479.1M | ||
| Q4 24 | $730.5M | $459.9M | ||
| Q3 24 | $702.5M | $430.1M | ||
| Q2 24 | $701.8M | $401.0M | ||
| Q1 24 | $659.2M | $378.6M |
净利润AMRXNET
| Q4 25 | $35.1M | $-12.1M | ||
| Q3 25 | $2.4M | $-1.3M | ||
| Q2 25 | $22.4M | $-50.4M | ||
| Q1 25 | $12.2M | $-38.5M | ||
| Q4 24 | $-31.1M | $-12.8M | ||
| Q3 24 | $-156.0K | $-15.3M | ||
| Q2 24 | $6.0M | $-15.1M | ||
| Q1 24 | $-91.6M | $-35.5M |
毛利率AMRXNET
| Q4 25 | 36.5% | 73.6% | ||
| Q3 25 | 34.9% | 74.0% | ||
| Q2 25 | 39.5% | 74.9% | ||
| Q1 25 | 36.8% | 75.9% | ||
| Q4 24 | 36.0% | 76.4% | ||
| Q3 24 | 38.4% | 77.7% | ||
| Q2 24 | 35.6% | 77.8% | ||
| Q1 24 | 36.1% | 77.5% |
营业利润率AMRXNET
| Q4 25 | 13.8% | -8.0% | ||
| Q3 25 | 9.0% | -6.7% | ||
| Q2 25 | 15.4% | -13.1% | ||
| Q1 25 | 14.4% | -11.1% | ||
| Q4 24 | 10.4% | -7.5% | ||
| Q3 24 | 12.6% | -7.2% | ||
| Q2 24 | 13.6% | -8.7% | ||
| Q1 24 | -1.6% | -14.4% |
净利率AMRXNET
| Q4 25 | 4.3% | -2.0% | ||
| Q3 25 | 0.3% | -0.2% | ||
| Q2 25 | 3.1% | -9.8% | ||
| Q1 25 | 1.8% | -8.0% | ||
| Q4 24 | -4.3% | -2.8% | ||
| Q3 24 | -0.0% | -3.6% | ||
| Q2 24 | 0.9% | -3.8% | ||
| Q1 24 | -13.9% | -9.4% |
每股收益（稀释后）AMRXNET
| Q4 25 | $0.10 | $-0.03 | ||
| Q3 25 | $0.01 | $0.00 | ||
| Q2 25 | $0.07 | $-0.15 | ||
| Q1 25 | $0.04 | $-0.11 | ||
| Q4 24 | $-0.10 | $-0.05 | ||
| Q3 24 | $0.00 | $-0.04 | ||
| Q2 24 | $0.02 | $-0.04 | ||
| Q1 24 | $-0.30 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $943.5M |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $1.5B |
| 总资产 | $3.7B | $6.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXNET
| Q4 25 | $282.0M | $943.5M | ||
| Q3 25 | $201.2M | $1.1B | ||
| Q2 25 | $71.5M | $1.5B | ||
| Q1 25 | $59.2M | $204.5M | ||
| Q4 24 | $110.6M | $147.7M | ||
| Q3 24 | $74.0M | $182.9M | ||
| Q2 24 | $43.8M | $157.0M | ||
| Q1 24 | $46.5M | $254.4M |
总债务AMRXNET
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXNET
| Q4 25 | $-70.8M | $1.5B | ||
| Q3 25 | $-109.5M | $1.3B | ||
| Q2 25 | $-112.1M | $1.2B | ||
| Q1 25 | $-131.7M | $1.4B | ||
| Q4 24 | $-109.3M | $1.0B | ||
| Q3 24 | $-93.4M | $973.1M | ||
| Q2 24 | $-57.5M | $881.5M | ||
| Q1 24 | $-63.7M | $797.2M |
总资产AMRXNET
| Q4 25 | $3.7B | $6.0B | ||
| Q3 25 | $3.6B | $5.8B | ||
| Q2 25 | $3.4B | $5.6B | ||
| Q1 25 | $3.4B | $3.7B | ||
| Q4 24 | $3.5B | $3.3B | ||
| Q3 24 | $3.5B | $3.1B | ||
| Q2 24 | $3.5B | $2.9B | ||
| Q1 24 | $3.5B | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $190.4M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $105.2M |
| 自由现金流率自由现金流/营收 | 13.3% | 17.1% |
| 资本支出强度资本支出/营收 | 2.7% | 13.9% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $287.5M |
8季度趋势，按日历期对齐
经营现金流AMRXNET
| Q4 25 | $130.3M | $190.4M | ||
| Q3 25 | $118.5M | $167.1M | ||
| Q2 25 | $83.8M | $99.8M | ||
| Q1 25 | $7.4M | $145.8M | ||
| Q4 24 | $118.1M | $127.3M | ||
| Q3 24 | $141.8M | $104.7M | ||
| Q2 24 | $39.7M | $74.8M | ||
| Q1 24 | $-4.4M | $73.6M |
自由现金流AMRXNET
| Q4 25 | $108.5M | $105.2M | ||
| Q3 25 | $106.2M | $82.5M | ||
| Q2 25 | $61.0M | $39.9M | ||
| Q1 25 | $-5.8M | $59.9M | ||
| Q4 24 | $102.9M | $54.2M | ||
| Q3 24 | $124.8M | $54.5M | ||
| Q2 24 | $29.0M | $45.2M | ||
| Q1 24 | $-13.6M | $41.5M |
自由现金流率AMRXNET
| Q4 25 | 13.3% | 17.1% | ||
| Q3 25 | 13.5% | 14.7% | ||
| Q2 25 | 8.4% | 7.8% | ||
| Q1 25 | -0.8% | 12.5% | ||
| Q4 24 | 14.1% | 11.8% | ||
| Q3 24 | 17.8% | 12.7% | ||
| Q2 24 | 4.1% | 11.3% | ||
| Q1 24 | -2.1% | 11.0% |
资本支出强度AMRXNET
| Q4 25 | 2.7% | 13.9% | ||
| Q3 25 | 1.6% | 15.1% | ||
| Q2 25 | 3.2% | 11.7% | ||
| Q1 25 | 1.9% | 17.9% | ||
| Q4 24 | 2.1% | 15.9% | ||
| Q3 24 | 2.4% | 11.7% | ||
| Q2 24 | 1.5% | 7.4% | ||
| Q1 24 | 1.4% | 8.5% |
现金转化率AMRXNET
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
NET
| Sales Channel Directly To Consumer | $438.5M | 71% |
| Sales Channel Through Intermediary | $176.0M | 29% |
